Clinical Professor in Oncology, University Hospital of Southern Denmark, Esbjerg, Denmark.
Joined December 2019
- Tweets167
- Following239
- Followers238
- Likes117
Well-written and insightful paper every oncologist and clinician with frontline clinical workload should read - before burnout
Oncology is a demanding profession, asking a great amount of those practicing in the field. Oncology clinicians can set boundaries while still meeting ethical practice standards. Setting boundaries may ultimately allow clinicians to be more present & engaged while working, have more satisfaction with their work, & maintain personal well-being. Some great suggestions in this table & article ascopubs.org/doi/full/10.120…
Frede Donskov retweeted
Updated IO combo table after #ASCO2023 IO/TKI presentations. VEGF tx provides early disease control while Ipi provides durability. We need a way to harness the benefits of both approaches. @montypal @DrChoueiri @tompowles1 @motzermd @HHammersMD
Any suggestions for a training scheme @HowardGurney ?
Frede Donskov retweeted
Flere kvitter, når prisen på cigaretter ryger i vejret. Men prisen skal hoppe, så det kan mærkes - ellers har det ingen effekt. Så hjælp @sophieloehde og sundheden, @JeppeBruus:
Sæt prisen højt op, så vi kan få en #røgfrifremtid
#dkpol #sundpol
altinget.dk/sundhed/artikel/… – at Copenhagen, Denmark
Frede Donskov retweeted
I thought only astronauts, bond villains and tech billionaires appeared in TIME magazine. Some people are all 3 but David McDermott is certainly none of the above and still made it! @Uromigos gbr01.safelinks.protection.o…
Frede Donskov retweeted
Cytoreductive nephrectomy associated with longer OS in patients with #mRCC treated with immune checkpoint inhibitor (ICI) therapy in any line of therapy. A multicenter retrospective cohort study of 367 patients (CN+ST 232, ST alone 135). sciencedirect.com/science/ar… – at Vejprnice, Česká republika
Frede Donskov retweeted
The new Prime Minister of Italy.
Wow. xitter.cf/FuryOriental/status/15…
Very excited to see our work on molecular analysis in Clear Cell & Non-Clear Cell Real-World #Renal Cell Carcinoma just published in @actaoncol
Thanks to great collaborative effort w co-authors
doi.org/10.1080/0284186X.202…
@OncoAlert @DrChoueiri @montypal @brian_rini @TSteiniche
Frede Donskov retweeted
About the smile: the standing ovation also meant that people saw what I knew: behind every one of these bars is a patient. I know every name and have seen almost everyone. I know their stories and their children. And I believe many are cured because of this. #ESMO22 #ChalabiPlot
Awesome discussion!
Hello to those waking up on the west coast! Had a chance to discuss @DrChoueiri's outstanding presentation of #COSMIC313 at #ESMO22 in the presidential session. Here's a quick synopsis. 1st, what an AMAZING mtg this has been for #kidneycancer (slide credit: @ZeynepZengin) (1/10)
Frede Donskov retweeted
A waterfall plot or a tidal wave 🌊???? 🤩 😯
99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!!
#ESMO22 @myESMO @MyriamChalabi
Frede Donskov retweeted
#ESMO22 Presidential symposium - adjuvant nivo/ipi in #RCC by @motzermd:
- 15% pT2a g3/4, pT2b
- 5% sarcomatoid (pdl1 status pending)
- placebo arm 24-mos DFS rate 74% (note 67% in KN-564)
- 1 in 3 d/c due to drug tox
@DrChoueiri @montypal @neerajaiims @BradMcG04 @OncoAlert – at Paris, France
Great summary @montypal on adjuvant therapy in #renalcellcarcinoma
Grateful to @TheLancet for allowing us to publish our experience with #adjuvant #atezolizumab (#IMmotion010) simultaneous w the presentation by #AxelBex at #ESMO22. It's interesting to envision how this data impacts current landscape (link below): (1/10) thelancet.com/journals/lance…
Frede Donskov retweeted
Our 30-month #KYN564 adjuvant RCC trial is published @TheLancetOncol —led by @tompowles1, presented #GU22 @ASCO —Note HR 0.63 improved from 0.68, all subgroups HR<1, AND if we remove M1NED/N+/T4=> HR 0.68. Still significant/clinically relevant @OncoAlert
sciencedirect.com/science/ar…
Frede Donskov retweeted
Our @IMDConline paper outlining #cabozantinib activity post #immunotherapy combination treatment in #kcsm #kidneycancer is out in @ElsevierConnect Clinical Genitourinary Cancers..1/6🧵
clinical-genitourinary-cance…
Important study published. Leibovich and GRANT validated in ccRCC and non-ccRCC nationwide #kidneycancer cohort. Leibovich outperformed GRANT in predicting recurrence-free survival and should remain
standard approach to risk stratify patients. @oncoalert
doi.org/10.1111/iju.14859
Do we have a Litmus test to predict survival in localized kidney cancer?
🔸7653 patients: GRade, Age, Nodes, and Tumor score (GRANT) 🇩🇰
🔸Leibovich score outperformed the GRANT regarding RFS
@FDonskov @OncoAlert @Uroweb @urotoday @NessnAzawi @KidneyCancer
onlinelibrary.wiley.com/doi/…
Stong 5-yr data just published @KidneyCancer
CheckMate 214
🔸Durable-long-term efficacy with Nivo-IPI
🔸mFU 67.7 months
🔸mOS: 55.7 months (48% @5Y)
🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO+IPI regardless of IMDC
@JournalCancer @OncoAlert @DrChoueiri
acsjournals.onlinelibrary.wi…
Frede Donskov retweeted
CheckMate 214
🔸Durable-long-term efficacy with Nivo-IPI
🔸mFU 67.7 months
🔸mOS: 55.7 months (48% @5Y)
🔸After 3 years the probability of remaining alive for an additional 2 years ↗️ with NIVO+IPI regardless of IMDC
@JournalCancer @OncoAlert @DrChoueiri
acsjournals.onlinelibrary.wi…